Quiz|Articles|August 25, 2024
Targeted Pulse Quiz: August 25
Author(s)Morgan Bayer
Fact checked by: Tony Berberabe, MPH
Test your knowledge on the current pulse of oncology including FDA updates and breaking data with our Targeted Pulse Quiz.
Advertisement
Ready for the challenge? Let’s begin!
Question 1 of 4: What recent status did fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) receive from the FDA?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5
















